Literature DB >> 25440014

Risk factors for re-bleeding of aneurysmal subarachnoid hemorrhage: meta-analysis of observational studies.

Gobran Taha Ahmed Alfotih1, FangCheng Li2, XinKe Xu2, ShangYi Zhang2.   

Abstract

OBJECTIVE: The mortality of re-bleeding following aneurysmal subarachnoid hemorrhage is high, and surviving patients often have poor clinical condition and worse outcome than patients with a single bleed. In this study, we performed an updated systematic review and meta-analysis to determine the most common risk factors for re-bleeding in this patient population, with the goal of providing neurologists, neurosurgeons, neuro-interventionalists with a simple and fast method to evaluate the re-bleeding risk for aneurysmal subarachnoid hemorrhage.
METHOD: We conducted a thorough meta-analysis of the risk factors associated with re-bleeding or re-rupture of intracranial aneurysms in cases published between 2000 and 2013. Pooled mean difference was calculated for the continuous variables (age), and pooled odds ratio (OR) was calculated for categorical factors. If heterogeneity was significant (p<0.05), a random effect model was applied; otherwise, a fixed model was used. Testing for pooled effects and statistical significance for each potential risk factor were analyzed using Review Manager software.
RESULTS: Our literature search identified 174 articles. Of these, only seven retrospective studies met the inclusion criteria. These seven studies consisted of 2470 patients, 283 of which had aneurysmal re-bleeding, resulting in a weighted average rate of re-bleeding of 11.3% with 95% confidence interval [CI]: 10.1-12.6. In this population, sex (OR 1.46; 95% CI: 1.11-1.92), high systolic blood pressure [SBP] (OR 2.52; 95% CI: 1.40-4.53), aneurysm size (OR 3.00; 95% CI: 2.06-4.37), clinical condition (Hunt & Hess) (OR 4.94; 95% CI: 2.29,10.68), and Fisher grade (OR 2.29; 95% CI: 1.45, 3.61) were statistically significant risk factors for re-bleeding.
CONCLUSION: Sex, high SBP, high Fisher grade, aneurysm size larger than 10mm, and poor clinical condition were independent risk factors for aneurysmal re-bleeding. The importance of early aneurysm intervention and careful consideration of patient risk factors should be emphasized to eliminate the risk of re-bleeding and poor outcome.
Copyright © 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Cerebral aneurysm; Meta-analysis; Re-bleeding risk factor; Subarachnoid hemorrhage

Mesh:

Year:  2014        PMID: 25440014     DOI: 10.1016/j.pjnns.2014.08.002

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  5 in total

Review 1.  Interventions for altering blood pressure in people with acute subarachnoid haemorrhage.

Authors:  Mathias Maagaard; William K Karlsson; Christian Ovesen; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-11-17

2.  Differentiation of Cerebral Dissecting Aneurysm from Hemorrhagic Saccular Aneurysm by Machine-Learning Based on Vessel Wall MRI: A Multicenter Study.

Authors:  Xin Cao; Yanwei Zeng; Junying Wang; Yunxi Cao; Yifan Wu; Wei Xia
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

3.  Clinical significance of changes in IL-6, CRP and S100in serum and NO in cerebrospinal fluid insubarachnoid hemorrhage and prognosis.

Authors:  Wensheng Zhang; Leitao Sun; Lixin Ma; Zefu Li
Journal:  Exp Ther Med       Date:  2018-05-29       Impact factor: 2.447

4.  Elevated Glucose-Potassium Ratio Predicts Preoperative Rebleeding in Patients With Aneurysmal Subarachnoid Hemorrhage.

Authors:  Jiayin Wang; Qiangqiang Feng; Yinbin Zhang; Weizhi Qiu; Hongzhi Gao
Journal:  Front Neurol       Date:  2022-01-13       Impact factor: 4.003

5.  Benign Paroxysmal Positional Vertigo and Occult Subarachnoid Hemorrhage Complicated after Head Trauma.

Authors:  Qinghua Li; Shuangxing Hou; Hualan Yang
Journal:  Case Rep Med       Date:  2020-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.